Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: USA VC Firm With Over $4B AUM Invests Up to $20M in New Therapeutics, Devices, and Digital Health Opportunities

5 Sep

A venture capital firm with multiple USA offices has managed over $4 billion in total assets across 11 funds and the firm focuses on making equity investments into the life science and technology spaces from seed to late venture stage. The investment size is varied, and typically it ranges from $1 million to $20 million. The firm will invest in companies primarily based in the US.An innovation arm of a global company nurtures innovative ideas developed internally and also forms external partnerships with startups in fields that are strategically relevant for the company’s business objectives. These partnerships may include co-development, in-kind services and/or early stage financial investments. The firm partners with startups based anywhere in the world.

The firm is currently looking for new opportunities in the Biotech Therapeutics, Medical Devices and Digital Health sectors. The firm will also consider Diagnostics, but that will not be its focus. For Therapeutics and Medical Devices, the firm is extremely opportunistic in terms of subsectors and indications. The firm is interested in companies targeting orphan diseases. The firm is generally looking for companies in the pre-clinical stage of development, but it also considers companies that may already have performed clinical studies, as well as companies near commercial stages dependent on the case.

The firm primarily invests in private companies, and considers pre-revenue companies. The firm doesn’t have specific requirements for company’s management team or revenue.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Private Wealth Investment Firm Seeks Medtech and Digital Health Companies in All Areas of High Unmet Need

5 Sep

A private wealth investment firm based in the USA invests globally in medically related early-stage companies. Initial size of investment largely varies depending on the deal’s stage of development and other involved investors.

The firm invests in medtech and digital health companies. While the founder has decades of experience as an oculofacial plastic surgeon, the firm is generally opportunistic and will consider any promising technologies that address unmet medical need. The firm has looked at AI companies, digital health/software companies implementable in medical practices, etc. In terms of stage of development, the firm is open to investing as early as pre-prototype, given that the company has properly researched the idea behind their technology.

The firm has no specific company or management team requirements. While the firm generally co-invests alongside a syndicate, the firm has led a financing before and is open to acting as the lead investor if the firm determines that they could add significant value.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Global Investment Firm Invests Up to $10M in Later Stage Therapeutics and Device Companies & Earlier Stage Opportunities with Strong Clinical Data

5 Sep

An investment firm with offices in USA, UK, and Asia, is actively seeking investment and partnership opportunities with therapeutics and medical device companies across the globe. Typical size of initial investment is around $5M, though the firm is capable of investing up to $10M and this is largely dependent on a case-by-case. The firm is capable of funding up to ~40% of the required amount for late stage clinical trials. The firm is also interested in-licensing partnerships and seek licensing and marketing rights on opportunities in which the firm can add significant value.

Within therapeutics and medical devices, the firm is generally sector and indication agnostic. The firm is focused on later-stage opportunities with a low risk profile, usually companies in Phase IIb and beyond. However, the firm is very keen to speaking with earlier stage opportunities that demonstrate strong clinical data and high potential to enter the global market and building a long-term relationship with these groups. In terms of medical devices, the firm will invest in near market ready products.

The firm seeks to invest in companies with experienced management teams with domain expertise, strong clinical data, and a clear exit strategy. The firm has an extensive professional network including fellow investors, high net worth individuals, clinical trial/regulatory affairs partners, etc. The firm takes a very active role in supporting their portfolio companies and provides mentorship and support on regulatory issues, market access, and effective clinical development strategies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: